


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound according to formula (I)



(I)

~~and the solvates, prodrugs, and pharmaceutically acceptable salts~~ or a solvate, prodrug or a pharmaceutically acceptable salt thereof, wherein

Ar is an unsubstituted or substituted phenyl group, 5-member heteroaryl group, 6-member heteroaryl group, 6,6-condensed ring aryl or heteroaryl group, or 6,5-condensed ring heteroaryl group;


each Q is independently N, CH, C(R⁶), where R⁶ is as defined hereinbelow, with the proviso that no more than two Q's are N;

each of R¹, R², R³, and R⁴ independently is H or a (C₁-C₅) alkyl group;

each R⁵ is independently H, a substituted or unsubstituted (C₁-C₁₂)alkyl group, or a substituted or unsubstituted (C₁-C₁₂) heteroalkyl group; and

each R⁶ is independently a substituted or unsubstituted (C₁-C₁₂) alkyl, OR⁵, N(R⁵)₂, O(CO)R⁵, N(CO)R⁵, Cl, F, or Br.


2. (Currently Amended) A compound according to claim 1, represented by the formula (II)




(II) :

3. (Original) A compound according to claim 1, wherein Ar is an unsubstituted or substituted phenyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, isothiazolyl, oxazolyl, isoxazolyl, thiazolyl, furazanyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, naphthyl, quinolyl, isoquinolyl, benzothienyl, indolyl, or benzofuranyl group.


4. (Original) A compound according to claim 1, wherein Ar is selected from the group consisting of




5. (Original) A compound according to claim 1, wherein the 6,5-condensed ring system



is selected from the group consisting of




6. (Currently Amended) A compound according to claim 1, wherein in the 6,5-condensed ring system




at least one Q is N.

7. (Currently Amended) A compound according to claim 1, represented by the formula (III):




(III).


8. (Currently Amended) A compound according to claim 1, represented by the formula (IV):




9. (Currently Amended) A compound according to claim 1, represented by the formula (V):



10. (Currently Amended) A compound according to claim 1, represented by the formula (VI):



11. (Currently Amended) A compound according to claim 1, represented by the formula (VII):



(VII):


12. (Original) A compound according to claim 1, wherein each of R^1 , R^2 , and R^3 is H.

13. (Original) A compound according to claim 1, wherein R^4 is methyl.


14. (Original) A compound according to claim 1, wherein R^5 is methyl, ethyl, propyl, isopropyl, $(CH_2)_n(Am)$, or $(CH_2)_n(OH)$, where n is 2, 3, 4, or 5 and Am is an alkyl amine group or a quaternary ammonium group.

15. (Original) A compound according to claim 14, wherein R^5 is $(\bar{C}H_2)_3(Am)$.


16. (Original) A compound according to claim 14, wherein R^5 is selected from the group consisting of



17. (Original) A compound according to claim 1, wherein R^5 is methyl, Ar is




and in the condensed 6,5 ring system



at least one Q is N and the remaining Q's are CH.


18. (Original) A compound according to claim 1, wherein Ar is selected from the group consisting of



and R⁵ is (CH₂)₃N(CH₃)₂.

19. (Original) A compound according to claim 1, wherein R⁶ is methyl, ethyl, propyl, isopropyl, OR⁵, NH(CO)R⁵, O(CO)R⁵, N(R⁵), or Cl.

20. (Original) A compound according to claim 1, wherein R⁶ is selected from the group consisting of:



21. (Original) A compound according to claim 1, having a minimum inhibitory concentration of 4 µg/mL or less against at least one of *Staphylococcus aureus* (ATCC 27660), *Streptococcus pneumoniae* (ATCC 51422), and *Enterococcus faecium* (ATCC 51559).

22. (Original) A method of treating a bacterial infection in a mammal, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

23. (Original) A method according to claim 22, wherein the bacterial infection is an infection by drug resistant bacteria.

24. (Original) A method according to claim 23, wherein the drug resistant bacteria is MRSA, PRSP, or VRE.

25. (Canceled)